OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021–Present)
Heba T. Abdel‐Mohsen, Manal M. Anwar, Nesreen S. Ahmed, et al.
Molecules (2024) Vol. 29, Iss. 4, pp. 875-875
Open Access | Times Cited: 10
Heba T. Abdel‐Mohsen, Manal M. Anwar, Nesreen S. Ahmed, et al.
Molecules (2024) Vol. 29, Iss. 4, pp. 875-875
Open Access | Times Cited: 10
Showing 10 citing articles:
Spiroindoline quinazolinedione derivatives as inhibitors of P-glycoprotein: potential agents for overcoming multidrug resistance in cancer therapy
Fatemeh Moosavi, Masoumeh Divar, Soghra Khabnadideh, et al.
Molecular Diversity (2025)
Closed Access | Times Cited: 1
Fatemeh Moosavi, Masoumeh Divar, Soghra Khabnadideh, et al.
Molecular Diversity (2025)
Closed Access | Times Cited: 1
Benzimidazole‐oxindole hybrids: A novel class of selective dual CDK2 and GSK‐3β inhibitors of potent anticancer activity
Heba T. Abdel‐Mohsen, Yasmin M. Syam, Mahmoud S. Abd El‐Ghany, et al.
Archiv der Pharmazie (2024) Vol. 357, Iss. 10
Closed Access | Times Cited: 8
Heba T. Abdel‐Mohsen, Yasmin M. Syam, Mahmoud S. Abd El‐Ghany, et al.
Archiv der Pharmazie (2024) Vol. 357, Iss. 10
Closed Access | Times Cited: 8
Quinazoline‐oxindole hybrids as angiokinase inhibitors and anticancer agents: Design, synthesis, biological evaluation, and molecular docking studies
Yasmin M. Syam, Somaia S. Abd El‐Karim, Heba T. Abdel‐Mohsen
Archiv der Pharmazie (2024) Vol. 357, Iss. 10
Closed Access | Times Cited: 7
Yasmin M. Syam, Somaia S. Abd El‐Karim, Heba T. Abdel‐Mohsen
Archiv der Pharmazie (2024) Vol. 357, Iss. 10
Closed Access | Times Cited: 7
Discovery of novel diaryl urea-oxindole hybrids as BRAF kinase inhibitors targeting BRAF and KRAS mutant cancers
Iman A. Y. Ghannam, Ahmed M. El Kerdawy, Marwa M. Mounier, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107848-107848
Closed Access | Times Cited: 6
Iman A. Y. Ghannam, Ahmed M. El Kerdawy, Marwa M. Mounier, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107848-107848
Closed Access | Times Cited: 6
Green synthesis, in silico modeling, and biological evaluation of N-substituted (Z)-5-arylidene imidazolidine/thiazolidine-2,4-dione/4-thione derivatives catalyzed by Bu SO3H core–shell nanostructures
Malihe Akhavan, Zohreh Esam, Atefeh Mirshafa, et al.
RSC Advances (2024) Vol. 14, Iss. 32, pp. 22916-22938
Open Access | Times Cited: 4
Malihe Akhavan, Zohreh Esam, Atefeh Mirshafa, et al.
RSC Advances (2024) Vol. 14, Iss. 32, pp. 22916-22938
Open Access | Times Cited: 4
Diphenyl urea‐benzylidene acetohydrazide hybrids as fibroblast growth factor receptor 1 inhibitors and anticancer agents
Heba T. Abdel‐Mohsen, Amira M. Nageeb, Iman A. Y. Ghannam
Drug Development Research (2024) Vol. 85, Iss. 6
Closed Access | Times Cited: 4
Heba T. Abdel‐Mohsen, Amira M. Nageeb, Iman A. Y. Ghannam
Drug Development Research (2024) Vol. 85, Iss. 6
Closed Access | Times Cited: 4
Design and synthesis of novel 2-S-alkylated Quinazolinones as dual BRAFV600E and EGFR inhibitors in melanoma: Mechanistic insights from apoptosis and cell cycle modulation
Hamed W. El-Shafey, Mohammad M. Al‐Sanea, Mohamed R. Elnagar, et al.
Bioorganic Chemistry (2025), pp. 108526-108526
Closed Access
Hamed W. El-Shafey, Mohammad M. Al‐Sanea, Mohamed R. Elnagar, et al.
Bioorganic Chemistry (2025), pp. 108526-108526
Closed Access
The antibreast cancer therapeutic potential of quinazoline hybrids–Part I
Wei Chen, Ruo Wang, Yidan Lin, et al.
Future Medicinal Chemistry (2025), pp. 1-15
Closed Access
Wei Chen, Ruo Wang, Yidan Lin, et al.
Future Medicinal Chemistry (2025), pp. 1-15
Closed Access
Benzimidazole–dioxoisoindoline conjugates as dual VEGFR-2 and FGFR-1 inhibitors: design, synthesis, biological investigation, molecular docking studies and ADME predictions
Heba T. Abdel‐Mohsen, Amira M. Nageeb
RSC Advances (2024) Vol. 14, Iss. 39, pp. 28889-28903
Open Access | Times Cited: 3
Heba T. Abdel‐Mohsen, Amira M. Nageeb
RSC Advances (2024) Vol. 14, Iss. 39, pp. 28889-28903
Open Access | Times Cited: 3
Oxindole–benzothiazole hybrids as CDK2 inhibitors and anticancer agents: design, synthesis and biological evaluation
Heba T. Abdel‐Mohsen
BMC Chemistry (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 2
Heba T. Abdel‐Mohsen
BMC Chemistry (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 2
Pd-catalysed regioselective cross dehydrogenative coupling of quinazolinones with aromatic carboxylic acids
Deepali S. Waghmare, Priyanka M. Lagad, Umesh A. Kshirsagar, et al.
Tetrahedron Letters (2024) Vol. 147, pp. 155214-155214
Closed Access
Deepali S. Waghmare, Priyanka M. Lagad, Umesh A. Kshirsagar, et al.
Tetrahedron Letters (2024) Vol. 147, pp. 155214-155214
Closed Access
Design, synthesis, and antiproliferative activity of new 1,2,3-triazole/quinazoline-4-one hybrids as dual EGFR/BRAFV600E inhibitors
Amira M. Mohamed, Ola M. F. Abou‐Ghadir, Yaser A. Mostafa, et al.
RSC Advances (2024) Vol. 14, Iss. 52, pp. 38403-38415
Open Access
Amira M. Mohamed, Ola M. F. Abou‐Ghadir, Yaser A. Mostafa, et al.
RSC Advances (2024) Vol. 14, Iss. 52, pp. 38403-38415
Open Access
